Home > Ozempic GLP-1 Lawsuit
Were You (or a Loved One) Diagnosed with Gastroparesis (Stomach Paralysis), Ileus (Bowel Obstruction), Deep Vein Thrombosis (DVT) or NAION (Sudden Vision Loss Eye Injury) After Taking Ozempic, Mounjaro, Wegovy, Rybelsus or Other GLP-1 Meds?
Ozempic GLP-1 Injury Lawsuits & Settlements
Reviewed by Jacobs Kolton, Chtd. Attorneys at Law; Updated June 2026
The Ozempic and GLP-1 lawsuits involve claims that manufacturers of medications such as Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity, Zepbound, and Saxenda failed to adequately warn patients and doctors about potential risks of developing gastroparesis (stomach paralysis), ileus (bowel obstruction), deep vein thrombosis (DVT), intraoperative pulmonary aspiration and NAION eye injury (sudden vision loss).
Our team of drug injury lawyers and class action attorneys is investigating potential Ozempic lawsuit cases and settlement claims of individuals who suffered stomach paralysis (gastroparesis), bowel obstruction (ileus), intraoperative pulmonary aspiration, other gastrointestinal problems, vision loss, deep vein thrombosis or pulmonary embolism after using Ozempic or other GLP-1 agonists.
If you (or a loved one) were diagnosed with gastroparesis (stomach paralysis), ileus (bowel obstruction), intraoperative pulmonary aspiration, deep vein thrombosis (DVT), pulmonary embolism (PE), or NAION sudden vision loss after taking Ozempic, Mounjaro, Wegovy or Rybelsus, you may be entitled to recover compensation from an Ozempic lawsuit case or settlement claim.
Ozempic (semaglutide) is a prescription drug in a class of medications called GLP-1 agonists (a/k/a glucagon-like peptide-1 receptor agonists, GLP-1 receptor agonists GLP-1-RA, incretin mimetics, or GLP-1 analogs) that have been used to treat type 2 diabetes and obesity by lowering blood sugar, helping the pancreas produce more insulin, and slowing the rate that food passes through the body. They work by binding to and activating GLP-1 receptors in cells to trigger the production of insulin (a hormone which converts glucose into energy) and suppressing the release of glucagon (a hormone that raises blood sugar). Other GLP-1 agonists include Mounjaro, Wegovy, and Rybelsus.
In recent years, billions of dollars have been spent on (and tens of millions of prescriptions have been written for) Ozempic and other GLP-1 agonists. Unfortunately, patients who took Ozempic or other diabetes and/or weight loss drugs may potentially be at an increased risk of developing severe gastrointestinal side effects, such as gastroparesis (stomach paralysis), ileus (intestinal obstruction or decrease or stoppage of flow of intestinal contents), intraoperative pulmonary aspiration (entry of liquid or solid material in trachea or lungs) and other GI injuries.
Injured patients (and families of loved ones who died) are now coming forward and filing Ozempic GLP-1 lawsuits seeking compensation and justice for the harm and suffering they may have endured.
Ozempic GLP-1 Injury Lawsuits: Overview
- What Is The Ozempic Lawsuit About?
- What Is Ozempic (Semaglutide)?
- What Other GLP-1 Agonist Drugs Treat Diabetes or Weight Loss?
- Are Attorneys Investigating Ozempic GLP-1 Injury Cases?
- Who May Qualify for an Ozempic Lawsuit or Settlement?
- What Are Some Key Facts To Know About Ozempic Lawsuits?
- What Injuries May Be Linked to Ozempic & Other GLP-1 Agonists?
- What Companies Have Been Sued For GLP-1 Injuries?
- Which Medications May Be Involved In The GLP-1 Litigation?
- What is The Status of The GLP-1 Ozempic Lawsuits?
- Can I Recover Compensation From an Ozempic Lawsuit?
- Can Families Recover Money in Ozempic Wrongful Death Cases?
- Is There A Deadline To File an Ozempic Lawsuit?
- Request A Free Case Review From An Ozempic GLP-1 Injury Lawyer
Ozempic and GLP-1 Lawsuit & Settlement Cases
Ozempic lawsuit cases and settlement claims potentially being investigated by attorneys include claims involving individuals who, after taking Ozempic, Mounjaro, Wegovy and/or other GLP-1 receptor agonist medications for diabetes and/or weight loss, suffered injury or complications, including:
- Gastroparesis
- Stomach paralysis
- Frozen stomach
- Delayed gastric emptying
- Intraoperative pulmonary aspiration
- Gastric stasis
- Gastroenteritis
- Ileus
- Intestinal obstruction
- Gastric blockage
- Bowel obstruction
- Severe and persistent vomiting
- Cyclical vomiting
- Severe and persistent diarrhea
- Severe and persistent nausea
- Gallbladder disease
- Gallbladder removal
- Esophageal injury requiring surgery
- GI injury requiring surgery
- Other gastrointestinal problems
- Hair loss
- Deep vein thrombosis (DVT)
- Pulmonary embolism (PE)
- Sudden vision loss
- Non-Arteritic Anterior Ischemic Optic Neuropathy
- NAION
- Eye injuries
- Death
- Other Ozempic injury lawsuit cases
If you or someone you love suffered injury or complications as a result of taking Ozempic, Mounjaro, Wegovy or other GLP-1 medications, you may be eligible to recover compensation from a GLP-1 agonist Mounjaro, Wegovy or Ozempic lawsuit or settlement case.
Who May Qualify For An Ozempic GLP-1 Lawsuit
Individuals may qualify for an Ozempic GLP-1 lawsuit case or settlement claim if they (or a loved one):
- Used Ozempic or Other GLP-1 Products: Took a GLP-1 (glucagon-like peptide-1) medication such as Ozempic (semaglutide), Mounjaro (tirzepatide), Wegovy (semaglutide), Rybelsus (semaglutide), Trulicity (dulaglutide), Zepbound (tirzepatide) or Saxenda (liraglutide).
- Suffered Injury or Death After Using GLP-1: Suffered injury after taking a GLP-1 medication, including gastroparesis (stomach paralysis), ileus (intestinal bowel obstruction), intraoperative pulmonary aspiration (entry of liquid or solid material in trachea or lungs), other GI injury that required surgery, non-arteritic anterior ischemic optic neuropathy (NAION) eye injury (sudden, permanent vision loss) or deep vein thrombosis (DVT) and related injuries, including pulmonary embolism (blood clot in lung) and/or death.
Other criteria may apply in order to be eligible. Not all individuals or cases qualify for an Ozempic GLP-1 lawsuit. Individuals may not qualify if: (1) medical factors or other factors make it difficult to link the injuries to a GLP-1; (2) they did not take a brand name GLP-1; (3) did not suffer injury while taking the GLP-1 or within 6 months of stopping it; (4) used only compounded GLP-1 products; (5) were 76 years of age or older when diagnosed with injury; (6) did not have inpatient medical care, ER or hospitalization; (7) for gastroparesis, do not have a gastric emptying study GES to support the diagnosis; (8) the claim is outside the statute of limitations or statute of repose period (if an individual waits too long they may be legally barred from suing); and/or (9) medical records do not support the claims. Individuals may not qualify for other reasons.
GLP-1 Lawsuits: Summary of Key Information
| Key Information | What It Means |
|---|---|
| GLP-1 Medication | GLP-1 receptor agonists medications are prescription drugs that mimic a natural hormone called glucagon-like peptide-1, which helps regulate blood sugar, insulin release, appetite and digestion. These drugs are used to treat type 2 diabetes, obesity and related metabolic conditions. |
| GLP-1 Brands | GLP-1 brands include Ozempic (semaglutide), Mounjaro (tirzepatide), Wegovy (semaglutide), Rybelsus (semaglutide), Trulicity (dulaglutide), Zepbound (tirzepatide) and Saxenda (liraglutide). |
| Ozempic GLP-1 Lawsuit | A legal action brought by plaintiffs (injured individuals or certain surviving family members or heirs of a deceased individual) against one or more defendant (the sued party) alleging that they suffered from gastroparesis, ileus, bowel obstruction, intraoperative pulmonary aspiration, NAION vision loss, DVT, pulmonary embolism and other possible injuries after taking Ozempic or other GLP-1 medication. |
| Who May Be Eligible | Individuals may qualify if they used a brand-name GLP-1 medication and later suffered a serious injury such as gastroparesis, ileus, aspiration, NAION vision loss, DVT, pulmonary embolism, another severe GI injury, or death. Eligibility depends on medical records, timing, diagnosis, and other case-specific facts. |
| Possible Injuries | Potential injuries include gastroparesis, stomach paralysis, delayed gastric emptying, ileus, bowel obstruction, severe vomiting, intraoperative pulmonary aspiration, gallbladder injuries, DVT, pulmonary embolism, NAION sudden vision loss, other eye injuries and death. |
| Potential Defendants | Potential defendants may include Novo Nordisk, Eli Lilly and others. |
| Alleged Wrongdoing | Lawsuits may allege that drug manufacturers knew or should have known that GLP-1 medications could cause or contribute to gastroparesis, NAION and other serious injuries, but failed to provide adequate warnings to patients and healthcare providers. |
| Possible Legal Claims | Legal claims may include negligence, strict liability, failure to warn, design defect, consumer protection violations, fraudulent concealment, misrepresentation, wrongful death, survival claims, and other possible claims. |
| Helpful Evidence | Helpful evidence may include prescription records, pharmacy records, medical records, hospitalization records, ER records, gastric emptying study results, surgical records, ophthalmology records, imaging, blood clot diagnosis records, doctor notes, proof of expenses, lost income records, and documentation showing when symptoms began. |
| Possible Compensation | Depending on the facts of the case and jurisdiction, injured individuals (or certain surviving family members or heirs of a deceased individual) may seek compensation for medical bills for hospitalization, surgery and other medical treatment, other expenses, lost wages or income, reduced earning capacity, pain and suffering, emotional distress, loss of enjoyment of life, wrongful death damages and other possible damages. |
| Status of Litigation | Ozempic GLP-1 lawsuits are being filed in state and federal courts. Federal GLP-1 gastrointestinal injury lawsuits are centralized in MDL No. 3094 in the Eastern District of Pennsylvania before Judge Karen S. Marston. Federal NAION vision-loss cases are centralized separately in MDL No. 3163, also before Judge Marston. Attorneys are still investigating new Ozempic GLP-1 injury cases. |
| Settlements & Verdicts | No global Ozempic or GLP-1 lawsuit settlement has been announced. Settlements, verdicts, or case results in one case do not guarantee a similar result in any future lawsuit. Each case depends on its own facts, evidence, injuries, medication use, history, medical records, defendant, court rulings, and applicable law. |
Ozempic/GLP-1 Injury Lawsuit Complaints
More than a thousand individuals who have taken GLP-1 receptor agonist medications (such as Ozempic, Mounjaro, Wegovy, and Rybelsus) to treat diabetes and/or obesity have filed lawsuits seeking to recover money damages for injuries they claim to have suffered as a result of their using the diabetes and/or weight loss drugs.
Plaintiffs in the Ozempic lawsuits allege, among other things, that they suffered gastrointestinal and other injuries after receiving GLP-1 receptor agonists, such as Ozempic, Wegovy, Rybelsus and Mounjaro and that defendants knew or should have known that GLP-1 RA drugs can cause gastroparesis and other injuries but failed to provide an adequate warning. The Ozempic lawsuit complaints assert claims for, among other things, negligence, strict liability, breach of warranty, negligent/fraudulent misrepresentation, and violation of state statutes.
| Legal Claim | What Plaintiffs May Allege |
|---|---|
| Negligence | Plaintiffs may claim that manufacturers failed to use reasonable care in researching, testing, monitoring, labeling, marketing, or selling GLP-1 drugs. |
| Strict Liability | Plaintiffs may claim the drugs were unreasonably dangerous when sold because of inadequate warnings or alleged product defects. |
| Design Defect | Some Plaintiffs may allege the drug’s design or formulation created an unreasonable risk of serious injuries. |
| Misrepresentation | Some Plaintiffs may allege manufacturers concealed, minimized, or misrepresented risks associated with GLP-1 drugs. |
| Breach of Express Warranty | Plaintiffs may claim manufacturers made specific promises or representations about the drugs’ safety or benefits that the drugs allegedly failed to meet. |
| Breach of Implied Warranty | Plaintiffs may allege the drugs were not reasonably safe or fit for their intended use when prescribed and taken as directed. |
| Other Legal Claims | Plaintiffs may assert other legal claims in GLP-1 lawsuits. |
Ozempic lawsuits filed in federal court alleging GI injuries have been transferred into a multidistrict litigation (MDL) for consolidation and coordination of pretrial proceedings to the Eastern District of Pennsylvania in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL Case No. 3094 (Judge Karen S. Marston). Federal GLP-1 lawsuits alleging non-arteritic anterior ischemic optic neuropathy (NAION) injuries have also been transferred into a separate MDL for consolidation and coordination before Judge Marston, styled as IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, MDL Case No. 3163.
GLP-1 injury lawsuit cases pending in state court have also been consolidated for pre-trial proceedings. For example, the New Jersey Supreme Court entered an order that designated all pending and future GLP-1 gastrointestinal-injury cases as multicounty litigation (MCL) and centralized them in Bergen County for coordinated management before Judge Gregg A. Padovano. Separately, the NJ Supreme Court approved an MCL for Ozempic/Wegovy vision-loss cases (NAION and related eye injuries), coordinating those cases before a single judge as well.
GLP-1 Medication Brands
Ozempic lawsuit and settlement cases potentially being investigated include claims involving individuals who suffered from gastroparesis, stomach problems or other injury (such as vision loss, deep vein thrombosis or pulmonary embolisms) after taking Ozempic and/or other GLP-1 medications to treat diabetes and/or obesity, including:
- Ozempic (semaglutide)
- Mounjaro (tirzepatide)
- Wegovy (semaglutide)
- Rybelsus (semaglutide)
- Trulicity (dulaglutide)
- Zepbound (tirzepatide)
- Saxenda (liraglutide)
- Other GLP-1 agonist medications
- Other diabetes or weight loss drug lawsuit cases
Diabetics, weight loss patients and other individuals who were diagnosed with gastroparesis (stomach paralysis) or suffered other injury (e.g., vision loss, deep vein thrombosis, pulmonary embolism, etc.) after taking Ozempic, Mounjaro, Wegovy and/or other GLP-1 receptor agonist medications may qualify.
Companies Sued For Ozempic or Other GLP-1 Injury
Defendants named in GLP-1 injury lawsuits have included manufacturers, sellers and/or distributors of various GLP-1 receptor agonist medications, including:
- Novo Nordisk (Ozempic, Rybelsus, Wegovy, Saxenda)
- Eli Lilly (Mounjaro, Zepbound, Trulicity)
- Other GLP-1 injury defendants
Ozempic GLP-1 Lawsuit & Settlement Updates
Recent updates about Ozempic lawsuits and settlements include:
- May 2026: GLP-1 lawsuits remain active in federal and state courts. According to the U.S. Judicial Panel on Multidistrict Litigation, there were 3,636 gastroparesis and other stomach and GI related cases in the GLP-1 gastrointestinal injury MDL and 86 NAION cases in the GLP-1 eye injury vision loss MDL, as of May 1, 2026. DVT and pulmonary embolism claims are not currently part of the federal MDLs after the JPML declined to expand that MDL to include those injuries.
- April 2026: As of April 1, 2026, there were 3,546 GLP-1 cases in the GLP-1 MDL for gastroparesis and other stomach and GI related injuries and 73 cases in the GLP-1 MDL for NAION optic eye injuries.
- December 2025: There are now 2,947 Ozempic/GLP-1 lawsuit cases pending in the Ozempic GLP-1 MDL.
- August 2025: As of August 1, 2025, 2,190 Ozempic/GLP-1 lawsuit cases were pending in the Ozempic/GLP-1 MDL proceeding. On August 15, 2025, Judge Marston issued several key rulings in the GLP-1 litigation. She denied defendants’ requests for judicial notice and to strike, and granted in part/denied in part defendant’s motion to dismiss. The express and implied warranty and negligent-undertaking counts survive; fraud/omission and misrepresentation claims may proceed when tied to the FDA-approved labels or consumer weight-loss messaging, but theories based on vague extra-label communications and several other counts were dismissed with leave to amend (including UPL/PLA buckets, general negligence, and medical monitoring). The Judge also granted defendants’ Daubert motions excluding two plaintiffs’ expert witnesses, denied plaintiffs’ motion to strike defense expert Dr. Nguyen, and granted plaintiffs’ motion to supplement. Thus, any plaintiff claiming to have had drug-induced gastroparesis must have had a gastric emptying study (scintigraphy, breath test, or WMC) properly performed at the time of their diagnosis, which confirmed delayed emptying.
- November 2024: Plaintiffs in the Ozempic lawsuit cases filed a new master complaint against defendants.
- October 2024: The Court issued a new scheduling order setting deadlines for fact discovery, expert discovery, and motions to exclude expert testimony and motions for summary judgment.
- July 2024: The Court held a status conference and issued various case management orders regarding plaintiff fact sheets, a protective order, a Rule 502d order, dismissal of certain defendants, and the direct filing of Ozempic/GLP-1 cases, among others.
- May 2024: On May 17, 2024, attorneys for plaintiffs filed a status report informing the Court on the status of the parties’ discussions regarding the terms of a proposed Plaintiff Fact Sheet (“PFS”), selection of vendors to handle PFS information, authorizations for release of medical records and collection of medical records, and various discovery related orders, among other things.
- April 2024: On April 9, 2024, the parties filed joint suggestions for an April 18 conference with the Court that was held, including an update on case inventory, science day, motion practice, fact sheets, electronic service, discovery and scheduling additional status conferences.
- March 2024: On March 14, 2024, the Court held an initial case management conference to discuss, among other things, various organizational and procedural issues, such as leadership structure for the plaintiffs, plaintiff fact sheets about the different GLP-1 receptor drugs that may have been taken and the alleged injuries that plaintiffs claim to have suffered as a result of taking the medications.
Older Ozempic lawsuit and settlement updates
- September 2023: On September 22, 2023, the FDA approved a drug label change indicating that Ozempic has the potential to lead to gastrointestinal disorders including Ileus (a non-mechanical bowel obstruction).
- March 2022: In March of 2022, the FDA approved a drug label change indicating that acute events of gallbladder disease such as cholelithiasis (gallstones) or cholecystitis (inflammation of the gallbladder) have been reported in GLP-1 receptor agonist trials and postmarketing and that in placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with Ozempic 0.5 mg and 1 mg, respectively
Compensation For GLP-1 & Ozempic Injury Claims
Plaintiffs who bring GLP-1 Ozempic lawsuits may be able to recover compensation for injuries suffered, including money damages for losses incurred as a result of taking Ozempic and other GLP-1 drugs, such as:
- Compensatory damages for pain and suffering
- Loss of wages or earnings due to missed work
- Loss of future earning capacity
- Medical care expenses incurred or to be incurred
- Other out of pocket expenses
- Loss of quality or enjoyment of life
- Mental anguish/emotional distress
- Loss of consortium
- Other possible GLP-1/Ozempic monetary damages
Certain family and loved ones of individuals who may have died as a result of taking Ozempic or other GLP-1 medications may be able to recover financial compensation from a GLP-1 Ozempic wrongful death lawsuit or settlement claim.
GLP-1 and Ozempic wrongful death lawsuit damages might include, among other things, pecuniary losses suffered by a surviving spouse or next of kin of the deceased family member, such as past and future loss of money or income, benefits, goods, services, and loss of society (i.e., the mutual benefits that each family member receives from the other’s continued existence, including love, affection, care, attention, companionship, comfort, guidance, and protection).
Time Is Limited To File An Ozempic Lawsuit
Deadlines known as statutes of limitation and statutes of repose may limit the time that individuals have to file a GLP-1 agonist or Ozempic lawsuit to try to recover compensation for injuries they claim to have suffered (e.g., stomach paralysis or other injury) after taking Ozempic and/or other similar diabetes or diet/weight loss drugs.
This means that if an Ozempic lawsuit claim is not filed before the applicable deadline or limitations period, the injured party may be barred from ever pursuing litigation or taking legal action regarding their Ozempic injury claim. That is why it is important to connect with an Ozempic injury lawyer or attorney as soon as possible.
If you or a loved one have suffered from gastroparesis (stomach paralysis), ileus, intraoperative pulmonary aspiration or other problems after taking Ozempic, Mounjaro, Wegovy, or Rybelsus, you may be entitled to recover compensation from an Ozempic lawsuit case or settlement claim. Contact a drug injury lawyer to request a free case review.
*If you or a loved one are experiencing health issues, side effects or complications after taking a prescription drug or medication, we urge you to promptly consult with your doctor or physician for an evaluation.
**The listing of a company (e.g., Novo Nordisk, Eli Lilly) or product (e.g., Ozempic, Mounjaro, Wegovy, Rybelsus, Trulicity, Saxenda or Zepbound) is not meant to state or imply that the company acted illegally or improperly or that the product is unsafe or defective; rather only that an investigation may be, is or was being conducted to determine whether legal rights have been violated.
***The use of any trademarks, tradenames or service marks is solely for product identification and/or informational purposes.
Fill out the form to request a free attorney review.